Galderma Labs Drug Patent Portfolio
Galderma Labs owns 2 orange book drugs protected by 14 US patents Given below is the list of Galderma Labs's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US8729127 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US9381179 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US9387187 | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 23 Dec, 2022 | Expired |
| US8785420 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions | 23 Dec, 2022 | Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris | 23 Dec, 2022 | Expired |
| US8909305 | Method and system for activating an application on a mobile device | 23 Dec, 2022 | Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Dec, 2022 | Expired |
| US9814690 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Dec, 2022 | Expired |
| US7700081 | Foaming compositions for hair care | 03 Jan, 2022 | Expired |
| US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle | 17 Jun, 2019 | Expired |
| US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle | 17 Jun, 2019 | Expired |
| US8066976 | Foaming compositions for hair care | 17 Jun, 2019 | Expired |
Latest Legal Activities on Galderma Labs's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Galderma Labs.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 04 Mar, 2024 | US9387187 |
|
Maintenance Fee Reminder Mailed
Critical
| 26 Feb, 2024 | US9381179 |
|
Expire Patent
Critical
| 01 Jan, 2024 | US8066976 |
|
Expire Patent
Critical
| 01 Jan, 2024 | US8066975 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US8066976 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US8066975 |
|
Expire Patent
Critical
| 23 May, 2022 | US7700081 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8909305 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2022 | US8809305 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jan, 2022 | US8785420 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Dec, 2021 | US7700081 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Apr, 2021 | US9814690 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Sep, 2020 | US8445543 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Dec, 2019 | US9387187 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2019 | US9381179 |
Galderma Labs Drug Patents' Oppositions Filed in EPO
Galderma Labs drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 05, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP07787478A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08708470A | Mar, 2016 | Generics (U.K.) Limited | Revoked |
| EP07787478A | Mar, 2014 | Generics [UK] Limited | Opposition rejected |
Galderma Labs's Family Patents
Galderma Labs drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 26.1% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Galderma Labs Drug List
Given below is the complete list of Galderma Labs's drugs and the patents protecting them.
1. Clobex
Clobex is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7700081 | Foaming compositions for hair care |
03 Jan, 2022
(2 years ago)
| Expired |
| US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
17 Jun, 2019
(5 years ago)
| Expired |
| US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
17 Jun, 2019
(5 years ago)
| Expired |
| US8066976 | Foaming compositions for hair care |
17 Jun, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clobex's drug page
2. Epiduo Forte
Epiduo Forte is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US8729127 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US9381179 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US9387187 | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
23 Dec, 2022
(2 years ago)
| Expired |
| US8785420 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
23 Dec, 2022
(2 years ago)
| Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
23 Dec, 2022
(2 years ago)
| Expired |
| US8909305 | Method and system for activating an application on a mobile device |
23 Dec, 2022
(2 years ago)
| Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(2 years ago)
| Expired |
| US9814690 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epiduo Forte's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List